Paper40587482
The distribution characteristics of PD-1 pathway-related immune cells in esophageal cancer tissue and their prognostic significance.
Kong D and 8 others. PLoS One, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. The distribution characteristics of PD-1 pathway-related immune cells in esophageal cancer tissue and their prognostic significance. Papers, record 40587482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40587482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The distribution characteristics of PD-1 pathway-related immune cells in esophageal cancer tissue and their prognostic significance.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Programmed Cell Death 1 Receptor | Major topic |
| Esophageal Neoplasms | Major topic |
| Humans | |
| Female | |
| Male | |
| Prognosis | |
| Middle Aged | |
| Aged | |
| Forkhead Transcription Factors | |
| B7-H1 Antigen | |
| Interleukin-2 Receptor alpha Subunit | |
| Biomarkers, Tumor | |
| Lymphatic Metastasis | |
| Kaplan-Meier Estimate | |
| Adult | |
| Lymphocytes, Tumor-Infiltrating |
Source PubMed
References63
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33302322 | Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy. | Eur J Immunol | 2021 | https://conductscience.org/library/papers/33302322 | PubMed |
| 2 | 26718132 | Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells. | Oncol Rep | 2016 | https://conductscience.org/library/papers/26718132 | PubMed |
| 3 | 37907738 | CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37907738 | PubMed |
| 4 | 36159781 | Roles of CD4+ T cells as mediators of antitumor immunity. | Front Immunol | 2022 | https://conductscience.org/library/papers/36159781 | PubMed |
| 5 | 36480211 | Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups. | JAMA Oncol | 2023 | https://conductscience.org/library/papers/36480211 | PubMed |
| 6 | 30888929 | PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. | Hum Vaccin Immunother | 2019 | https://conductscience.org/library/papers/30888929 | PubMed |
| 7 | 37820583 | CD8+ T cells in the cancer-immunity cycle. | Immunity | 2023 | https://conductscience.org/library/papers/37820583 | PubMed |
| 8 | 24751582 | The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. | Am J Gastroenterol | 2014 | https://conductscience.org/library/papers/24751582 | PubMed |
| 9 | 32965635 | Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. | Clin J Gastroenterol | 2020 | https://conductscience.org/library/papers/32965635 | PubMed |
| 10 | 30296523 | PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. | Hum Pathol | 2019 | https://conductscience.org/library/papers/30296523 | PubMed |
| 11 | 37668710 | PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/37668710 | PubMed |
| 12 | 30551854 | Risk factors for oesophageal cancer. | Best Pract Res Clin Gastroenterol | 2018 | https://conductscience.org/library/papers/30551854 | PubMed |
| 13 | 36082452 | CD25: A potential tumor therapeutic target. | Int J Cancer | 2023 | https://conductscience.org/library/papers/36082452 | PubMed |
| 14 | 35771261 | Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/35771261 | PubMed |
| 15 | 30713780 | IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner. | Oncoimmunology | 2019 | https://conductscience.org/library/papers/30713780 | PubMed |
| 16 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 17 | 33725774 | A low proportion of regulatory T cells before chemoradiotherapy predicts better overall survival in esophageal cancer. | Ann Palliat Med | 2021 | https://conductscience.org/library/papers/33725774 | PubMed |
| 18 | 34307133 | FOXP3 Inhibits the Metastasis of Breast Cancer by Downregulating the Expression of MTA1. | Front Oncol | 2021 | https://conductscience.org/library/papers/34307133 | PubMed |
| 19 | 25638546 | Anti-PD-L1 antibody active in metastatic bladder cancer. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25638546 | PubMed |
| 20 | 37812328 | Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise. | Curr Gastroenterol Rep | 2023 | https://conductscience.org/library/papers/37812328 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41089601 | Multicenter validation of CEACAM6 and FOXP3 as robust prognostic biomarkers in colon cancer: Combined immunohistochemical and transcriptomic analysis. | Mol Clin Oncol | 2025 | https://conductscience.org/library/papers/41089601 |
Source PubMed
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| IL2RA | 3559 | PubTator's text mining | https://conductscience.org/library/genes/3559 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40587482
GET https://conductscience.org/api/papers/v1/40587482/references?page=2